Highline Wealth Partners’s Edwards Lifesciences EW Stock Holding History

Highline Wealth Partners’s Portfolio EW Stock Details EW Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$8.32K	Buy	92 +10	+12%	+$838	﹤0.01%	687
2026 Q1	$6.57K	Sell	82 -3	-4%	-$247	﹤0.01%	627
2025 Q4	$7.25K	Buy	85 +49	+136%	+$4.02K	﹤0.01%	465
2025 Q3	$2.8K	Hold	36	–	–	﹤0.01%	778
2025 Q2	$2.82K	Sell	36 -17	-32%	-$1.27K	﹤0.01%	576
2025 Q1	$3.84K	Buy	53 +20	+61%	+$1.43K	﹤0.01%	489
2024 Q4	$2.44K	Sell	33 -160	-83%	-$11.2K	﹤0.01%	429
2024 Q3	$12.7K	Buy	193 +169	+704%	+$12.3K	﹤0.01%	225
2024 Q2	$2.22K	Buy	24 +3	+14%	+$266	﹤0.01%	382
2024 Q1	$2.01K	Hold	21	–	–	﹤0.01%	330
2023 Q4	$1.6K	Hold	21	–	–	﹤0.01%	315
2023 Q3	$1.46K	Hold	21	–	–	﹤0.01%	290
2023 Q2	$1.98K	Hold	21	–	–	﹤0.01%	227
2023 Q1	$1.74K	Hold	21	–	–	﹤0.01%	237
2022 Q4	$1.57K	Hold	21	–	–	﹤0.01%	238
2022 Q3	$1.74K	Buy	+21	New	+$2.02K	﹤0.01%	220

Other funds holding EW

Ninety One (UK) London, United Kingdom $44.7B AUM 17.24% 1-Year Est. Return

Wellcome Trust London, United Kingdom $9.01B AUM 12.05% 1-Year Est. Return

Assenagon Asset Management Senningerberg, Luxembourg $80.2B AUM 50.57% 1-Year Est. Return

Handelsbanken Fonder Stockholm, Sweden $35.1B AUM 47.76% 1-Year Est. Return

BHIA

Birch Hill Investment Advisors Boston, Massachusetts $2.47B AUM 20.95% 1-Year Est. Return

NONA

Ninety One North America New York $2.13B AUM 9.16% 1-Year Est. Return

Robeco Institutional Asset Management Rotterdam, Netherlands $81.4B AUM 40.71% 1-Year Est. Return

SIM

Seilern Investment Management London, United Kingdom $794M AUM 6.63% 1-Year Est. Return

OIAM

OFI Invest Asset Management Paris, France $10B AUM 48.47% 1-Year Est. Return

FFM

Fisher Funds Management Auckland, New Zealand $3.52B AUM 17.59% 1-Year Est. Return

Highline Wealth Partners's EW Position: Q2 2026 in Review

Highline Wealth Partners increased its Edwards Lifesciences (EW) stake by 12% in Q2 2026, buying an estimated $838 and bringing the position to 92 shares worth $8.32K. The position accounts for ﹤0.01% of the portfolio, ranked #687.

Highline Wealth Partners first reported a position in EW in Q3 2022 and has held it in 16 quarters since. The position peaked at $12.7K in Q3 2024. 287 funds tracked by Wall St. Rank hold EW as of Q2 2026.

Highline Wealth Partners held 92 shares of Edwards Lifesciences worth $8.32K as of Q2 2026.
Highline Wealth Partners bought 10 Edwards Lifesciences shares in Q2 2026, an estimated $838.
Edwards Lifesciences made up ﹤0.01% of Highline Wealth Partners's portfolio in Q2 2026, its #687 holding.
Highline Wealth Partners first reported a position in Edwards Lifesciences in Q3 2022 and has held it in 16 quarters since.
Highline Wealth Partners's Edwards Lifesciences position peaked at $12.7K in Q3 2024.
287 funds tracked by Wall St. Rank held Edwards Lifesciences as of Q2 2026.

Based on Highline Wealth Partners's 13F filing for Q2 2026, filed 15 Jul 2026.